Last Updated2026-06-02

Market View

₹2,299(▼0.91%)

Reporting PeriodQ4 FY26

MANKINDMankind Pharma Limited Forensic Risk Analysis

Name: Mankind Pharma Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market Cap₹92,881 Cr

Primary DriverBalance Sheet Stress

Flagium AI Risk Score

15 / 100

-5 QoQ

Improving

Sentinel Insight

Financial profile remains stable for now. Pressure is receding in balance sheet stress. This indicates that forensic pressure is currently receding. Risk levels are improving.

40.4th %ile (Sector)Accel: +0 Qtrs

Updated2026-06-02

Market View

₹2,299▼0.91%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress

+8.8 pts

Stability Adjustment

+6.0 pts

Final Composite Risk15 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 15 over 12 quarters.

Expected Direction

🟢 Improving

Primary Deterioration Drivers

Margin Compression
Industrial Margin Stress
Operating Leverage Stress

What to Watch Next Quarter

Debt growth
Operating profit margins
Working capital efficiency

Active Risk Objects (4)

CriticalHigh

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 4 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ3 FY2026

Expenses are consistently growing faster than revenues, creating operational pressure.

"The balance sheet is heavily over-leveraged. Interest payments are consuming most of the profit."

Margin Compression

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight15/15

MomentumPersistent

Last SignalQ2 FY2026

Operating margin declined by 10.2 bps YoY for two consecutive quarters.

"Margins are in freefall. Operating costs are growing significantly faster than revenue."

Industrial Margin Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight12/15

MomentumAccelerating

Last SignalQ1 FY2026

MANKIND: EBITDA margin compressed by 1.6 bps YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 5 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ4 FY2026

Working capital expansion detected: Receivable days increased by 5.3%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	7.73	7.70	⚠️ HIGH
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+51.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹2,299(-0.91%)

1M Divergence+0.06%

1 Week-5.14%

1 Month+2.33%

6 Months+4.2%

1 Year-4.74%

2 Year+7.48%

3 Year+56.86%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

MANKIND • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.12%

Trend QualityEarly Base

Phase Progression

Phase Progression Score30%

Readiness LabelLow (Early Base Consolidation)

Probability of Advancing12%

CoinTree Momentum

Composite Z-Score-0.1309σ

Weakening momentum trend

Universe Rank#1261 of 2716

Top 46.43% in momentum strength

Timeframe Sparklines

1W-5.1%

1M+2.3%

6M+4.2%

Weinstein Indicators

150 DMA₹2,211.6

200 DMA₹2,287.42

150 DMA Slope-0.2882%Declining

Relative Strength+9.62%Leading

Relative Turnover (RTR)1.5640

ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
MANKINDMankind Pharma Limited	15	40th	-5	4	+0	Balance Sheet StressStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch
AARTIPHARMAarti Pharmalabs Limited	35	81th	0	18	+0	Earnings QualityWatch
ALBERTDAVDAlbert David Limited	37	90th	-8	27	+0	Balance Sheet StressWatch